Join Growin Stock Community!

Phio pharmaceuticals corp.PHIO.US Overview

US StockHealthcare
(No presentation for PHIO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PHIO AI Insights

PHIO Overall Performance

PHIO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PHIO Recent Performance

6.44%

Phio pharmaceuticals corp.

1.63%

Avg of Sector

0.63%

S&P500

PHIO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PHIO Key Information

PHIO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PHIO Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Price of PHIO

PHIO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PHIO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.74
PE Ratio (TTM)
-
Forward PE
0.31
PS Ratio (TTM)
48.01
PB Ratio
1.19
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.74
PE Ratio (TTM)
-
Forward PE
0.31
PS Ratio (TTM)
48.01
PB Ratio
1.19
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PHIO's latest earnings report released?

    The most recent financial report for Phio pharmaceuticals corp. (PHIO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PHIO's short-term business performance and financial health. For the latest updates on PHIO's earnings releases, visit this page regularly.

  • How much cash does PHIO have?

    At the end of the period, Phio pharmaceuticals corp. (PHIO) held Total Cash and Cash Equivalents of 10.71M, accounting for 0.93 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PHIO's EPS continuing to grow?

    According to the past four quarterly reports, Phio pharmaceuticals corp. (PHIO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.44. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PHIO?

    Phio pharmaceuticals corp. (PHIO)'s Free Cash Flow (FCF) for the period is -2.09M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 7.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PHIO?

    The latest valuation data shows Phio pharmaceuticals corp. (PHIO) has a Price-To-Earnings (PE) ratio of -1.94 and a Price/Earnings-To-Growth (PEG) ratio of 6.38. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.